Vasogen ACCLAIM trial
This article was originally published in The Gray Sheet
Executive Summary
Double-blind, placebo-controlled Phase III study examining impact of firm's Celacade immune modulation technology on the risk of death and cardiovascular hospitalization in patients with advanced chronic heart failure has reached full enrollment of 2,000 patients, Vasogen announces May 5. Quest Diagnostics has invested in Celacade through a joint U.S. commercialization pact (1"The Gray Sheet" Nov. 26, 2001, p. 33)...
You may also be interested in...
Vasogen Sees 2003 PMA For Vascular Disease Immune Modulation Therapy
Vasogen plans to submit a premarket approval application in 2003 for its immune modulation therapy (IMT) for peripheral arterial disease (PAD)
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.